A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder

International Clinical Psychopharmacology

Volumn 23, Issue 5, 2008, Pages 269-275

  Garakani, Amir ^a   Martinez, Jose M ^a   Marcus, Sue ^a   Weaver, James ^a   Rickels, Karl ^b   Fava, Maurizio ^c   Hirschowitz, Jack ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adjunct; Atypical antipsychotic; Depression; Insomnia; Selective serotonin reuptake inhibitor

Indexed keywords

FLUOXETINE; PLACEBO; QUETIAPINE; ANTIDEPRESSANT AGENT; DIBENZOTHIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADD ON THERAPY; ADULT; ANXIETY; ARTHRALGIA; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEDATION; SIDE EFFECT; TREATMENT RESPONSE; XEROSTOMIA; ADOLESCENT; AGED; COMPARATIVE STUDY; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOLOGICAL RATING SCALE; REGRESSION ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 54449093654     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328301a74c     Document Type: Article

References (51)

1. Agargun MY, Kara H, Solmaz M (1997). Sleep disturbances and suicidal behavior in patients with major depression. J Clin Psychiatry 58:249-251.
2. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004). Consensus development conference on anti-psychotic drugs and obesity and diabetes. J Clin Psychiatry 65:267-272.
3. American Psychiatric Association (2000). Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157 (Suppl 4):1-45.
4. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T (2004). Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 65:464-470.
5. Arvanitis LA, Miller BG (1997). Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 42:233-234.
6. Ballesteros J, Callado LF (2004). Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J Affect Disord 79:137-147.
7. Barnes TR (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
8. Baune BT, Caliskan S, Todder D (2007). Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum Psycho-pharmacol 22:1-9.
9. Beasley CM Jr, Koke SC, Nilsson ME, Nilsson ME, Gonzales JS (2000). Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depression: an updated meta-analysis. Clin Ther 22:1319-1330.
10. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, et al. (2007). The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68:843-853.
11. Blier P (2003). The pharmacology of putative early-onset antidepressant strategies. Eur Neuropsychopharmacol 13:57-66.
12. Chouinard G, Chouinard VA (2008). Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom 77:69-77.
13. Cohrs S, Rodenbeck A, Guan Z, Pohlmann K, Jordan W, Meier A, et al. (2004). Sleep-promoting properties of quetiapine in healthy subjects. Psycho-pharmacology 174:421-429.
14. Correll CU, Leucht S, Kane JM (2004). Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161:414-425.
15. Crossley NA, Bauer M (2007). Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 68:935-940.
16. Cusin C, Fava M, Amsterdam JD, Quitkin FM, Reimherr FW, Beasley CM Jr, et al. (2007). Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications. J Clin Psychiatry 68:52-57.
17. Devarajan S, Ali J, Dursun SM (2006). Quetiapine plus SSRI in treatment-resistant depression: possible mechanisms [letter]. Psychopharmacology 185:402-403
18. Dorée JP, Des Rosiers J, Lew V, Gendron A, Elie R, Stip E, et al. (2007). Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin 23:333-341.
19. Fava M (2001). Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry 62 (Suppl 18):4-11.
20. Fava M (2003). Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53:649-659.
21. Fava M (2004). Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry 65 (Suppl 16):27-32.
22. Fava M, Rush AJ (2006). Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom 75:139-153.
23. Fava M, Rosenbaum J, McCarthy M, Pava J, Steingard R, Bless E (1991). Anger attacks in depressed outpatients. Psychopharmacol Bull 27:275-279.
24. Gibbons RD (2000). Mixed-effects models for mental health services research. Health Serv Outcomes Res Methodol 1:91-129.
25. Goldstein JM, Christoph G, Grimm S, Liu JW, Widzowski D, Brecher M (2007). Unique mechanism of action for the antidepressant properties of the atypical antipsychotic quetiapine. Proc 62nd Annu Soc Biol Psychiatry Sci Conven Meet. . Abstract NR404:124S-125S.
26. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health Education and Welfare, No. (ADM). pp. 76-338.
27. Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32:50-55.
28. Hedeker D, Gibbons RD (1996). MIXREG: a computer program for mixed-effects regression analysis with autocorrelated errors. Comput Methods Programs Biomed 49:229-252.
29. Hirschfeld RM, Weisler RH, Raines SR, Macfadden W, for the BOLDER Study Group (2006). Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 67:355-362.
30. Katz MM, Tekell JL, Bowden CL, Brannan S, Houston JP, Berman N, et al. (2004). Onset and early behavioral effects of pharmacologically different antidepres-sants and placebo in depression. Neuropsychopharmacology 29:566-579.
31. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602.
32. Leon AC (2001). Measuring onset of antidepressant action in clinical trials: an overview of definitions and methodology. J Clin Psychiatry 62 (Suppl 4): 12-16.
33. Marek GJ, Carpenter LL, McDougle CJ, Price LH (2003). Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuro-psychiatric disorders. Neuropsychopharmacology 28:402-412.
34. Mattingly GW, Ilivicky HJ, Canale JP, Anderson RH (2006). Quetiapine augmentation for treatment-resistant depression. Proceedings of the 159th Annual Meeting of the American Psychiatric Association. Abstract NR250. Presented May 22, 2006; Toronto, Ontario, Canada.
35. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, et al. (2000). The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 26:25-40.
36. McIntyre A, Gendron A, McIntyre A (2007). Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety 24:487-494.
37. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
38. Montgomery SA, Huusom AKT, Bothmer J (2004). A randomised study comparing escitalopram with venlafaxine XR in patients in primary care with major depressive disorder. Neuropsychobiology 50:57-64.
39. Nierenberg AA, Farabaugh AH, Alpert JE, Gordon J, Worthington JJ, Rosenbaum JF, et al. (2000). Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 157:1423-1428. Papakostas GI, Petersen TJ, Nierenberg AA, Murakami JL, Alpert JE, Rosenbaum F, et al. (2004). Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 65:217-221.
40. Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE, et al. (2005). Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry 66:1326-1330.
41. Papakostas GI, Shelton RC, Smith J, Fava M (2007). Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 68:826-831.
42. Posternak MA, Zimmerman M (2005). Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry 66:148-158.
43. Quitkin FM, Rabkin JG, Ross D, Stewart JW (1984). Identification of true drug response to antidepressants. Use of pattern analysis. Arch Gen Psychiatry 41:782-786.
44. Sagud M, Mihaljevic-Peles A, Muck-Seler D, Jakovljevic M, Pivac N (2006). Quetiapine augmentation in treatment-resistant depression: a naturalistic study. Psychopharmacology 187:511-514.
45. Saller CF, Salama AI (1993). Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 112:285-292.
46. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): he development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 (Suppl 20): 22-33.
47. Shelton RC (2007). Augmentation strategies to increase antidepressant efficacy. J Clin Psychiatryqe 68 (Suppl 10):18-22.
48. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212 (Suppl):11-19.
49. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z (2006). Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry 63:1217-1223.
50. Todder D, Caliskan S, Baune BT (2006). Night locomotor activity and quality of sleep in quetiapine-treated patients with depression. J Clin Psychopharmacol 26:638-642.
51. Zajecka JM (2007). Augmentation strategies to increase antidepressant tolerability. J Clin Psychiatry 68 (Suppl 10):23-27.